← Back to Patent Explorer
US4305922A Expired / Lapsed US ⏱️ 0.0 years remaining

Labeling proteins with 99m-Tc by ligand exchange

Assignee: Rhomed Inc
•
Filing: 1978-10-04
•
Granted: 1981-12-15
•
Expires: 1998-10-04
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A new method for labeling proteins with 99m-technetium: (1) Start with any volume of technetium (pertechnetate and saline) solution and add 0.1 ml of stannous solution (stannous fluoride-acetate solution) per 15-20 ml of saline. The stannous ions will reduce the pertechnetate to technetium IV. (2) Pour the solution onto a sterile Sephadex G-25 column, The reduced technetium (Tc-IV) will bind to the very top layer of Sephadex. (3) Wash the column with saline solution to remove any free pertechnetate or unusual species of technetium. (4) Add the protein in the minimum volume of water to the top of the Sephadex column. Wait 30 minutes. During this waiting period ligand exchange will occur and the technetium will become bound to the protein, but only to those sites on the protein that form a stronger ligand bond than the Sephadex. This means that the only product that will be formed will be technetium strongly bound to proteins. (5) Wash the labeled protein through the column by adding 1 cc of human serum albumin solution diluted 50/50 with ACD. (6) When this has all soaked into the column, add 5 cc of saline, which means that since the volume of the column is 5 cc there will be 6 cc of eluate. The last (or 6th) cc will contain the Tc-labeled human serum albumin. The impurities will remain on the column.

Inventors

  • 👤 Buck A. Rhodes

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 19:11
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/08; A61K51/0474; A61K51/0478; A61K51/081; A61K51/088; A61K2123/00; Y; Y10; Y10S; Y10S530/00; Y10S530/81; Y10S530/812; Y10S530/813; Y10S530/814

Claims Analysis

Total Claims: 14
Claim 1
Independent Claim 64 words
Method of labeling protein with technetium-99 m without denaturing the protein, which comprises forming a complex of technetium-99m IV with a water-insoluble chelating agent by contacting said chelating agent with a solution of technetium-99m IV, washing said complex to remove undesired ions, contacting said complex with an aqueous protein solution and separating the aqueous solution of protein labeled with technetium-99m IV from the complex.
Claim 2
Dependent Claim 64 words
Method of labeling protein with technetium-99 m without denaturing the protein, which comprises forming a complex of technetium-99m IV with a water-insoluble chelating agent by contacting said chelating agent with a solution of technetium-99m IV, washing said complex to remove undesired ions, contacting said complex with an aqueous protein solution and separating the aqueous solution of protein labeled with technetium-99m IV from the complex.
Claim 3
Dependent Claim 11 words
Method of claim 1 wherein the protein is human serum albumin.
Claim 4
Dependent Claim 10 words
Method of claim 1 wherein the protein is human fibrinogen.
Claim 5
Dependent Claim 21 words
Method of claim 1 wherein the chelating agent is a polymer of dextran cross-linked with epichlorohydrin, ethylene oxide or propylene oxide.
Claim 6
Dependent Claim 24 words
Method of claim 4 wherein the time of contact of the complex with aqueous protein solution is from about 5 to about 30 minutes.
Claim 7
Dependent Claim 12 words
99m Tc-labeled human fibrinogen wherein the Tc has a valence of 4.
Claim 8
Dependent Claim 12 words
99m Tc-labeled human fibrinogen wherein the Tc has a valence of 4.
Claim 9
Dependent Claim 20 words
A water-insoluble complex of 99m Tc IV and a polymer of dextran cross-linked with epichlorohydrin, ethylene oxide or propylene oxide.
Claim 10
Dependent Claim 20 words
A water-insoluble complex of 99m Tc IV and a polymer of dextran cross-linked with epichlorohydrin, ethylene oxide or propylene oxide.
Claim 11
Dependent Claim 13 words
99m Tc-labeled anti-human chorionic gonadotropin wherein the Tc has a valence of 4.
Claim 12
Dependent Claim 13 words
99m Tc-labeled anti-human chorionic gonadotropin wherein the Tc has a valence of 4.
Claim 13
Dependent Claim 13 words
99m Tc-labeled human anti-chorionic gonadotropin-beta wherein the Tc has a valence of 4.
Claim 14
Dependent Claim 13 words
99m Tc-labeled human anti-chorionic gonadotropin-beta wherein the Tc has a valence of 4.

References Cited (Backward Citations)

US3803299A Cited
US3862299A Cited
US3749556A Cited
US3902849A Cited
US4001387A Cited
US4042677A Cited
US4057617A Cited
US4094965A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1984-12-14 1985-06-15 1985-12-15 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1988-12-14 1989-06-15 1989-12-15 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1992-12-14 1993-06-15 1993-12-15 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag